Pfizer and BioNTech requested FDA emergency use authorization for a fourth COVID-19 dose for older adults; postpartum depression rates tripled during early months of the COVID-19 pandemic; anxiety and depression diagnoses among children each increased by roughly 25% since 2016.
Read More
AstraZeneca Receives CRL for Benralizumab in Chronic Rhinosinusitis With Nasal Polyps
March 16th 2022FDA issued a complete response letter (CRL) to AstraZeneca seeking additional clinical data for benralizumab, sold as Fasenra, in the treatment of patients with inadequately controlled chronic rhinosinusitis with nasal polyps.
Read More
Genetic RA Associated With Inflammatory Bowel Disease, but Not Other Way Around
March 16th 2022The genetically-predicted risk of rheumatoid arthritis (RA) was positively associated with an increased risk of inflammatory bowel disease (IBD) and potentially with its main subtypes, ulcerative colitis and Crohn disease.
Read More
More, Better Linkage to Care Needed to Optimize HIV-Related Support Outcomes
March 15th 2022This new meta-analysis from World Health Organization and University of Cape Town investigators analyzed adverse posthospitalization discharge outcomes and related risk factors among persons living with HIV.
Read More
Finerenone Reduces Heart Failure Risk in Patients With CKD, T2D
March 15th 2022Finerenone (Kerendia) was found to reduce risk of heart failure and improve other cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) regardless of heart failure history.
Read More
Idaho legislature passed Texas-inspired abortion law banning the procedure after 6 weeks of pregnancy; patients who were bedridden with severe cases of COVID-19 had increased risks of anxiety and depression more than a year later; number of deaths by suicide in Japanese women rose for second straight year.
Read More
Upadacitinib Shows Sustained Efficacy, Safety in Moderate to Severe Atopic Dermatitis
March 15th 2022Longer-term findings of the Measure Up 1 and 2 studies showed the JAK inhibitor upadacitinib to be safe and effective after 52 weeks in the treatment of adults and adolescents with moderate to severe atopic dermatitis.
Read More
Mount Sinai Researchers Discuss Milestones in Understanding Genetic Variants
March 14th 2022Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss their hopes for their findings and how genetic data are being used in health care.
Watch
Considerations to Increase Rates of Breast Cancer Screening Across Populations
Authors from the Community Oncology Alliance and Avalere Health present data that show breast cancer screening rates recovered more slowly among some racial/ethnic groups following on the onset of the COVID-19 pandemic.
Read More
Julie Reed Previews 2022: The Year of Expanded Access to Biosimilars
March 14th 2022As the United States awaits market introduction for adalimumab biosimilars in 2023, 2022 is going to be the year of expanding access to biosimilars, according to Julie M. Reed, the new executive director of the Biosimilars Forum.
Watch
Dr Kashyap Patel on Health Equity Discussion at the 2022 Community Oncology Conference
March 14th 2022Kashyap Patel, MD, chief executive officer, Carolina Blood and Cancer Care Associations, and current president of the Community Oncology Alliance (COA), previews his discussion on health equity to be held at the 2022 Community Oncology Conference.
Watch
Incidence of Nasal Polyps Linked With Severe Radiographic Disease in CRS
March 13th 2022Patients with chronic rhinosinusitis (CRS) with severe radiographic disease were more likely to report incidence of nasal polyps and be managed by endoscopic sinus surgery, but did not show greater health care utilization.
Read More
Potential Link Found Between Thrombotic Events, Mortality in Patients With PV, ET
March 13th 2022Patients with polycythemia vera (PV) or essential thrombocythemia (ET) had a higher risk of thrombotic events than the general population, which was associated with mortality in a recent study.
Read More
Dr Robert Sidbury on Psychosocial, Behavioral Issues Linked With Atopic Dermatitis
March 13th 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, discussed the psychosocial and behavioral issues faced by patients with atopic dermatitis, particularly those with severe disease.
Watch